BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  White House Science Adviser Resigns Following Bullying Reports

  After allegations of bullying became public, Dr. Eric Lander, the director of the federal government’s Office of Science and Technology Policy, resigned from his executive branch role.

  February 8, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Companies Making the Biggest Bucks from COVID-19 Therapeutics Sales

  Here’s a look at five companies that produced non-vaccine treatments for COVID-19.

  February 8, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Alzheon Alzheimer’s Asset Poised for Phase III with High Hopes

  ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer’s patients.

  February 8, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  After Watershed Year, Pfizer Expects Revenue to Top $98B in ’22

  The vaccine delivered more than $12 billion in revenue to Pfizer and the company expects those earnings to vastly increase this year to $32 billion.

  February 8, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Healx and Ovid Therapeutics Partner on Fragile X Therapy

  New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).

  February 8, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Zucara Reveals Hopeful Preclinical Data in Type 1 Diabetes

  Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.

  February 8, 2022

   · 

  2 min read

   · 

  Claudia Beezhold
• 

  Business

  Bayer Poaches GSK’s Christine Roth as Others Shuffle the Executive Deck

  Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.

  February 8, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  CRISPR Pioneer Doudna Joins Global Investment Firm as CSO

  Jennifer Doudna will act as Chief Science Advisor to build a Scientific Advisory Board for Sixth Street, advising the investment firm on CRISPR-related opportunities.

  February 8, 2022

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Amgen 2021 Revenue Propped up by COVID-19 Manufacturing Collab

  Much of Amgen’s modest gains in the year can be attributed to its manufacturing partnership with Eli Lilly and an increase in sales for EVENITY.

  February 8, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Pharm Country

  COVID Update: Pill Production Underway and Vaccines in Pregnant Women

  Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.

  February 8, 2022

   · 

  5 min read

   · 

  Mark Terry